Treatment of congenital Langerhans cell histiocytosis with cobimetinib.

Autor: Benjelloun G; Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium., Roquet-Gravy C; Department of Dermatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Marot L; Department of Anatomopathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Secco LP; Department of Anatomopathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Roquet-Gravy PP; Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium., Baeck M; Department of Dermatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Bulinckx A; Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2024 May-Jun; Vol. 41 (3), pp. 515-517. Date of Electronic Publication: 2024 Feb 22.
DOI: 10.1111/pde.15512
Abstrakt: We report a case of congenital multisystem Langerhans cell histiocytosis with cutaneous and hematopoietic involvement. After the failure of first-line (vinblastine and prednisolone) and second-line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen-activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: